| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Thoracic/Head and Neck Medical Oncology, Molecular Biology Laboratory, [W. W., Y-H. F., L. M.], Thoracic and Cardiovascular Surgery [G. W.], and Pathology [B. L. K.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Cyclin-dependent kinases can be activated by cdc25, which removes inhibitory phosphates from tyrosine and threonine residues. At least three cdc25 genes (cdc25A, cdc25B, and cdc25C) have been identified in humans. Accumulating evidence indicates that cdc25A and cdc25B possess oncogenic properties. Recently, overexpression of cdc25A and of cdc25B was found in many breast and head and neck cancers. To determine potential roles of cdc25s in non-small cell lung cancer (NSCLC), we analyzed primary tumors and corresponding normal lung tissues from 40 patients with NSCLC for relative expression levels of these genes by multiplex reverse transcription PCR (RT-PCR). cdc25A was overexpressed in 60% (24 of 40) of the tumors and cdc25B in 45% (18 of 40) of the tumors, whereas cdc25C was not overexpressed in any of the tumors analyzed. Because c-myc can increase cdc25A and cdc25B expression, it may be a factor in cdc25 overexpression. We found that c-myc was overexpressed in only 18% (7 of 40) of the tumors. We found no association between overexpression of c-myc and cdc25A or cdc25B. We also investigated whether the cdc25B gene was amplified in NSCLC and found this was true in 40% (8 of 20) of the tumors tested. However, this amplification was not correlated with gene expression status. Interestingly, among 24 tumors with cdc25A overexpression and 18 with cdc25B overexpression, 42% (10 of 24) and 44% (8 of 18) were poorly differentiated histological type. In contrast, well or moderately differentiated tumors had lower frequencies of cdc25A and cdc25B overexpression [19% (3 of 16) and 23% (5 of 22), respectively]. These data indicate that overexpression of cdc25A and cdc25B is frequent and that it may play an important role in NSCLC. However, it is unlikely that this overexpression is caused by c-myc stimulation or cdc25B gene amplification.
1 Supported in part by American Cancer Society Grant RPG-98-054, National Cancer Institute Grant PO1 CA74173, and The University of Texas M. D. Anderson Cancer Center Grant P30 CA16620.
2 To whom requests for reprints should be addressed, at Molecular Biology Laboratory, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6363; Fax: (713) 796-8865; E-mail: lmao@notes.madcc.tmc.edu.
Received 6/12/98. Accepted 7/30/98.
This article has been cited by other articles:
|
|
 |
|
  Z.-R. Yuan and Y. Shi Chloramphenicol Induces Abnormal Differentiation and Inhibits Apoptosis in Activated T Cells Cancer Res., June 15, 2008; 68(12): 4875 - 4881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ebi, K. Matsuo, N. Sugito, M. Suzuki, H. Osada, K. Tajima, R. Ueda, and T. Takahashi Novel NBS1 Heterozygous Germ Line Mutation Causing MRE11-Binding Domain Loss Predisposes to Common Types of Cancer Cancer Res., December 1, 2007; 67(23): 11158 - 11165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ray, Y. Terao, D. Nimbalkar, H. Hirai, E. C. Osmundson, X. Zou, R. Franks, K. Christov, and H. Kiyokawa Hemizygous Disruption of Cdc25A Inhibits Cellular Transformation and Mammary Tumorigenesis in Mice Cancer Res., July 15, 2007; 67(14): 6605 - 6611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ray, Y. Terao, P. G. Fuhrken, Z.-Q. Ma, F. J. DeMayo, K. Christov, N. A. Heerema, R. Franks, S. Y. Tsai, E. T. Papoutsakis, et al. Deregulated CDC25A Expression Promotes Mammary Tumorigenesis with Genomic Instability Cancer Res., February 1, 2007; 67(3): 984 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wali, R. Srinivasan, M. S. Shabnam, S. Majumdar, K. Joshi, and D. Behera Loss of Fragile Histidine Triad Gene Expression in Advanced Lung Cancer Is Consequent to Allelic Loss at 3p14 Locus and Promoter Methylation Mol. Cancer Res., February 1, 2006; 4(2): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ozen and M. Ittmann Increased Expression and Activity of CDC25C Phosphatase and an Alternatively Spliced Variant in Prostate Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4701 - 4706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ray, Y. Terao, D. Nimbalkar, L.-H. Chu, M. Donzelli, T. Tsutsui, X. Zou, A. K. Ghosh, J. Varga, G. F. Draetta, et al. Transforming Growth Factor {beta} Facilitates {beta}-TrCP-Mediated Degradation of Cdc25A in a Smad3-Dependent Manner Mol. Cell. Biol., April 15, 2005; 25(8): 3338 - 3347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Tse and G. K. Schwartz Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe Cancer Res., September 15, 2004; 64(18): 6635 - 6644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Han, H. Shen, B. I. Carr, P. Wipf, J. S. Lazo, and S.-s. Pan NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 64 - 70. [Abstract] [Full Text]
|
|
|
|
|
|
W. Wu, B. M. Slomovitz, J. Celestino, L. Chung, A. Thornton, and K. H. Lu Coordinate Expression of Cdc25B and ER-{alpha} Is Frequent in Low-Grade Endometrioid Endometrial Carcinoma but Uncommon in High-Grade Endometrioid and Nonendometrioid Carcinomas Cancer Res., October 1, 2003; 63(19): 6195 - 6199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Xiao, Z. Chen, A. H. Gunasekera, T. J. Sowin, S. H. Rosenberg, S. Fesik, and H. Zhang Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents J. Biol. Chem., June 6, 2003; 278(24): 21767 - 21773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xu, H. Yamamoto, M. Sakon, M. Yasui, C. Y. Ngan, H. Fukunaga, T. Morita, M. Ogawa, H. Nagano, S. Nakamori, et al. Overexpression of CDC25A Phosphatase Is Associated with Hypergrowth Activity and Poor Prognosis of Human Hepatocellular Carcinomas Clin. Cancer Res., May 1, 2003; 9(5): 1764 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Melkun, M. Pilione, and R. F. Paulson A naturally occurring point substitution in Cdc25A, and not Fv2/Stk, is associated with altered cell-cycle status of early erythroid progenitor cells Blood, November 15, 2002; 100(10): 3804 - 3811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cozma, L. Lukes, J. Rouse, T. H. Qiu, E. T. Liu, and K. W. Hunter A Bioinformatics-Based Strategy Identifies c-Myc and Cdc25A as Candidates for the Apmt Mammary Tumor Latency Modifiers Genome Res., June 1, 2002; 12(6): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Ma, Z. Liu, E. S. W. Ngan, and S. Y. Tsai Cdc25B Functions as a Novel Coactivator for the Steroid Receptors Mol. Cell. Biol., December 1, 2001; 21(23): 8056 - 8067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sato, H. Sasaki, S. Kondo, I. Fukai, M. Kiriyama, Y. Yamakawa, and Y. Fujii Expression of the cdc25B mRNA Correlated with that of N-myc in Neuroblastoma Jpn. J. Clin. Oncol., September 1, 2001; 31(9): 428 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Hu, K. Y. Lam, S. Law, J. Wong, and G. Srivastava Identification of Differentially Expressed Genes in Esophageal Squamous Cell Carcinoma (ESCC) by cDNA Expression Array: Overexpression of Fra-1, Neogenin, Id-1, and CDC25B Genes in ESCC Clin. Cancer Res., August 1, 2001; 7(8): 2213 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zou, T. Tsutsui, D. Ray, J. F. Blomquist, H. Ichijo, D. S. Ucker, and H. Kiyokawa The Cell Cycle-Regulatory CDC25A Phosphatase Inhibits Apoptosis Signal-Regulating Kinase 1 Mol. Cell. Biol., July 15, 2001; 21(14): 4818 - 4828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Chen, J. Hurov, L. S. White, T. Woodford-Thomas, and H. Piwnica-Worms Absence of Apparent Phenotype in Mice Lacking Cdc25C Protein Phosphatase Mol. Cell. Biol., June 15, 2001; 21(12): 3853 - 3861. [Abstract] [Full Text]
|
|
|
|
|
|
H. Miyata, Y. Doki, H. Yamamoto, K. Kishi, H. Takemoto, Y. Fujiwara, T. Yasuda, M. Yano, M. Inoue, H. Shiozaki, et al. Overexpression of CDC25B Overrides Radiation-induced G2-M Arrest and Results in Increased Apoptosis in Esophageal Cancer Cells Cancer Res., April 1, 2001; 61(7): 3188 - 3193. [Abstract] [Full Text]
|
|
|
|
|
|
H. Miyata, Y. Doki, H. Shiozaki, M. Inoue, M. Yano, Y. Fujiwara, H. Yamamoto, K. Nishioka, K. Kishi, and M. Monden CDC25B and p53 Are Independently Implicated in Radiation Sensitivity for Human Esophageal Cancers Clin. Cancer Res., December 1, 2000; 6(12): 4859 - 4865. [Abstract] [Full Text]
|
|
|
|
|
|
I. Takemasa, H. Yamamoto, M. Sekimoto, M. Ohue, S. Noura, Y. Miyake, T. Matsumoto, T. Aihara, N. Tomita, Y. Tamaki, et al. Overexpression of CDC25B Phosphatase as a Novel Marker of Poor Prognosis of Human Colorectal Carcinoma Cancer Res., June 1, 2000; 60(11): 3043 - 3050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mailand, J. Falck, C. Lukas, R. G. Syljuåsen, M. Welcker, J. Bartek, and J. Lukas Rapid Destruction of Human Cdc25A in Response to DNA Damage Science, May 26, 2000; 288(5470): 1425 - 1429. [Abstract] [Full Text]
|
|
|
|
 |
|
 I.B. Weinstein Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis Carcinogenesis, May 1, 2000; 21(5): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tamura, E. C. Southwick, J. Kerns, K. Rosi, B. I. Carr, C. Wilcox, and J. S. Lazo Cdc25 Inhibition and Cell Cycle Arrest by a Synthetic Thioalkyl Vitamin K Analogue Cancer Res., March 1, 2000; 60(5): 1317 - 1325. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Tseng, B. L. Kemp, F. R. Khuri, J. M. Kurie, J. S. Lee, X. Zhou, D. Liu, W. K. Hong, and L. Mao Loss of Fhit Is Frequent in Stage I Non-Small Cell Lung Cancer and in the Lungs of Chronic Smokers Cancer Res., October 1, 1999; 59(19): 4798 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Vigo, H. Muller, E. Prosperini, G. Hateboer, P. Cartwright, M. C. Moroni, and K. Helin CDC25A Phosphatase Is a Target of E2F and Is Required for Efficient E2F-Induced S Phase Mol. Cell. Biol., September 1, 1999; 19(9): 6379 - 6395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Korner, V. Jerome, T. Schmidt, and R. Muller Cell Cycle Regulation of the Murine cdc25B Promoter. ESSENTIAL ROLE FOR NUCLEAR FACTOR-Y AND A PROXIMAL REPRESSOR ELEMENT J. Biol. Chem., March 23, 2001; 276(13): 9662 - 9669. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
